A groundbreaking collaborative effort led by researchers from the Icahn School of Medicine at Mount Sinai and the Lieber Institute for Brain Development has unveiled a previously unknown biological mechanism underlying brain development abnormalities in individuals with Down syndrome. This international study, combining expertise from Mount Sinai, the Lieber Institute, the Medical University of Sofia in Bulgaria, and the University of Arizona, sheds new light on how trisomy 21, the genetic hallmark of Down syndrome, disrupts early neural formation through a novel RNA editing pathway.
Published in the prestigious journal Nature Communications, the research focuses on the gene ADARB1, which encodes an enzyme commonly referred to as ADAR2. This protein plays a crucial role in the post-transcriptional modification of RNA, a process known as RNA editing that alters RNA sequences after they are transcribed from DNA. The study reveals that in Down syndrome, the ADARB1 gene is overexpressed due to the presence of an additional copy of chromosome 21, resulting in elevated enzymatic activity. This heightened RNA editing occurs prematurely and excessively in developing fetal brain cells, profoundly influencing neuronal communication and the establishment of brain circuits.
Down syndrome stems from trisomy 21, wherein an extra chromosome 21 interferes with normal development. While the presence of the additional chromosome has been recognized for decades, the precise molecular pathways through which it skews brain developmental trajectories have remained obscure. This new research decisively links trisomy 21 to a dysregulation in RNA editing mediated by ADAR2, providing a direct molecular connection between gene dosage imbalance and neural circuit abnormalities.
Michael S. Breen, PhD, Associate Professor of Genetics and Genomic Sciences at Mount Sinai and a senior author on the study, emphasized the importance of these findings in reframing our understanding of Down syndrome neuropathology. “Our work illuminates how an extra chromosome reshapes the brain during critical prenatal stages by driving up levels of a key RNA editing enzyme. This leads to accelerated and aberrant editing of neuronal transcripts, which in turn likely affects how proteins function in developing brain cells and how neural networks are wired,” Breen stated.
The team rigorously investigated brain tissue samples collected at mid-gestation from 20 fetuses diagnosed with trisomy 21 and 27 unaffected controls. They concentrated on the prefrontal cortex and hippocampus, two regions critically implicated in cognition and memory, employing state-of-the-art RNA sequencing technologies to unravel gene expression and RNA editing patterns at unparalleled resolution. Their data demonstrated widespread gene expression disturbances in trisomy 21 brain samples, but notably identified ADARB1 as one of the most significantly upregulated genes, corresponding with enhanced RNA editing activity.
A particularly striking discovery was the abnormal editing found in glutamate and GABA receptor genes, including GRIA2, GRIA3, GRIK2, and GABRA3. These receptors are essential for excitatory and inhibitory neurotransmission, respectively, balancing neuronal network signaling. RNA recoding events—where single nucleotide alterations change protein amino acid sequences—were markedly increased in these receptor transcripts. Such modifications may disrupt the excitatory-inhibitory balance during a critical window when neural circuits are forming, potentially contributing to cognitive deficits seen in Down syndrome.
To validate their findings, the investigators integrated data from nine independent human trisomy 21 RNA datasets. This meta-analysis consistently revealed elevated ADARB1 expression and RNA editing across diverse cohorts, underscoring the robustness and reproducibility of their observations. These converging lines of evidence firmly establish ADARB1 overexpression and RNA editing dysregulation as core molecular signatures of Down syndrome brain pathology.
Beyond defining a novel biomolecular route affected by chromosome 21 triplication, the study pioneers RNA editing as a measurable biomarker of early brain circuit development. Joseph D. Buxbaum, PhD, a co-author and Professor at Mount Sinai, highlighted the transformative impact of this insight: “Identifying ADARB1-driven RNA editing abnormalities reshapes our view of Down syndrome neuropathology. It opens exciting new therapeutic avenues targeting RNA editing processes during fetal development, with the goal of ameliorating neurological and behavioral impairments.”
The implications of this research extend further, suggesting potential for precision medicine strategies. By leveraging RNA editing biomarkers, it may become feasible to track brain developmental trajectories noninvasively or to design interventions tailored to correct RNA editing imbalances. Such approaches could substantially improve quality of life and functional outcomes for individuals with Down syndrome.
The Mount Sinai Health System, a leading academic medical entity comprised of multiple hospitals and research centers, played a pivotal role in enabling this cutting-edge investigation. Its commitment to integrating clinical care and genomics was instrumental in securing and analyzing rare fetal brain specimens during mid-gestation, a crucial period that has historically been difficult to study in humans.
Similarly, the Lieber Institute for Brain Development, affiliated with Johns Hopkins University, provided unique expertise and access to an extensive human brain repository. Their collaborative environment fostered the multi-institutional research necessary to decode complex genetic and molecular underpinnings of neurodevelopmental disorders like Down syndrome.
In summary, this landmark study reveals how trisomy 21 causes an early and harmful surge in ADARB1-generated RNA editing within key neuronal genes, altering protein function and neural circuit assembly in the developing brain. Far from a peripheral consequence, RNA editing emerges as a central process disrupted by chromosome 21 duplication, redefining fundamental models of Down syndrome brain development and opening innovative paths for diagnosis and treatment.
Together, these advances underscore the power of international, interdisciplinary partnerships to unravel genetic disorders’ intricacies. Future work building on this foundation promises to move beyond characterization toward actionable solutions, bringing hope to millions affected by Down syndrome worldwide.
Subject of Research: People
Article Title: Trisomy 21 Drives ADARB1 Overexpression and Premature RNA Recoding in the Developing Fetal Brain
News Publication Date: 31-Mar-2026
Web References: Mount Sinai
References: DOI: 10.1038/s41467-026-70217-5
Image Credits: Michael Breen, PhD
Keywords: Down syndrome, RNA, Developmental genetics, ADARB1, ADAR2, RNA editing, trisomy 21, fetal brain development, neuronal signaling, glutamate receptors, GABA receptors, neurodevelopment
Tags: abnormal fetal brain development mechanismsADAR2 enzyme role in neural developmentADARB1 gene overexpression in fetal brainbrain circuit formation defects in trisomy 21international research on Down syndrome brain abnormalitiesNature Communications Down syndrome studyneuronal communication disruption in Down syndromepost-transcriptional RNA modification in Down syndromepremature RNA editing in neural cellsRNA editing dysregulation in Down syndromeRNA editing pathways in neurodevelopmental disorderstrisomy 21 impact on RNA editing
